Break it Down: Funding boost for Alterity’s MSA drug candidate
Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.
In this episode, host Tylah Tully unpacks news from Alterity Therapeutics (ASX:ATH), which has raised $20 million through a strategic placement to Australian and international professional investors.
Proceeds will strengthen Alterity’s balance sheet, fund key activities and the support the ongoing clinical development of the company’s lead drug candidate ATH-434, a treatment for Multiple System Atrophy, a rare and rapidly progressive Parkinsonian disorder.
Watch the video to learn more.
While Alterity Therapeutics is a Stockhead advertiser, it did not sponsor this content.
Related Topics
Related Stories
UNLOCK INSIGHTS
Discover the untold stories of emerging ASX stocks.
Daily news and expert analysis, it's free to subscribe.
By proceeding, you confirm you understand that we handle personal information in accordance with our Privacy Policy.
